Currently known TK fusion genes associated with myeloid/lymphoid neoplasms with eosinophilia and potential activity of TK inhibitors
| TKgene . | Rearranged chromosomal band . | Known partner genes (at least) . | Most frequent partner gene . | Preferably used inhibitors . | Risk for resistance/ progression/death . | Efficacy . |
|---|---|---|---|---|---|---|
| PDGFRA | 4q12 | 8 | FIP1L1 | Imatinib | Very low | +++ |
| PDGFRB | 5q31∼33 | >30 | ETV6 | Imatinib | Very low | +++ |
| FGFR1 | 8p11∼12 | 14 | ZMYM2 | Ponatinib | High | + |
| JAK2 | 9p24 | 4 | PCM1 | Ruxolitinib | Variable | ++ |
| ABL1 | 9q33 | 2 | ETV6 | Imatinib | Variable | ++ |
| Nilotinib | ||||||
| Dasatinib | ||||||
| FLT3 | 13q12 | 3 | ETV6 | Sorafenib | High | + |
| Sunitinib | ||||||
| Midostaurin |
| TKgene . | Rearranged chromosomal band . | Known partner genes (at least) . | Most frequent partner gene . | Preferably used inhibitors . | Risk for resistance/ progression/death . | Efficacy . |
|---|---|---|---|---|---|---|
| PDGFRA | 4q12 | 8 | FIP1L1 | Imatinib | Very low | +++ |
| PDGFRB | 5q31∼33 | >30 | ETV6 | Imatinib | Very low | +++ |
| FGFR1 | 8p11∼12 | 14 | ZMYM2 | Ponatinib | High | + |
| JAK2 | 9p24 | 4 | PCM1 | Ruxolitinib | Variable | ++ |
| ABL1 | 9q33 | 2 | ETV6 | Imatinib | Variable | ++ |
| Nilotinib | ||||||
| Dasatinib | ||||||
| FLT3 | 13q12 | 3 | ETV6 | Sorafenib | High | + |
| Sunitinib | ||||||
| Midostaurin |